

**REMARKS**

The specification has been amended to add priority information. The claims have been amended to more particularly point out and distinctly claim the subject matter applicants regard as the invention. Support for new claim 24 can be found throughout the application as filed. Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned "Version with markings to show changes made".

No new matter has been introduced.

Applicants believe that no fee is required for this submission. However, should a fee be due, please charge such fee to Deposit Account No. 08-3425.

Respectfully submitted

Date: JANUARY 25, 2002

  
Janet M. Martineau (Reg. No. 46,903)  
Attorney for Applicants

Human Genome Sciences, Inc.  
9410 Key West Avenue  
Rockville, MD 20850  
(301) 315-2723 (telephone)

KKH/JMM/CEW/mlm

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of: MOORE et al.

Attorney Docket No.: PZ032P1C3

Application Serial No.: To be assigned

Art Unit: To be assigned

Filed: January 25, 2002

Examiner: To be assigned

Title: 49 Human Secreted Proteins

**VERSION WITH MARKINGS TO SHOW CHANGES MADE****In the Specification**

On page 1, the first paragraph has been changed as follows:

This application is a continuation application of U.S. Application No. 09/904,615, filed July 16, 2001, which is a continuation of U.S. Application No. 09/739,254, filed December 19, 2000 which is a continuation of 09/511,554, filed February 23, 2000, which is a continuation-in-part of, and claims benefit under 35 U.S.C. § 120 of copending [United States patent application Serial No. PCT/US99/17130 filed July 29, 1999,] International patent Application Serial No. PCT/US99/19330, filed August 24, 1999, which is hereby incorporated by reference, which claims benefit under 35 U.S.C. § 119(e) based on U.S. Provisional Application Numbers 60/097,917, filed August 25, 1998 and 60/098,634 filed August 31, 1998, each of which are hereby incorporated by reference.

**In the Claims:**

Claim 17 has been amended as follows:

17. (Amended) A method for preventing, treating, or ameliorating a medical condition, comprising administering to a mammalian subject a therapeutically effective amount of the polypeptide of claim 11 [or the polynucleotide of claim 1].